Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNBX NASDAQ:CRE NASDAQ:ISPC NASDAQ:LICN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNBXApplied Dna Sciences$0.45-0.9%$0.51$0.35▼$7.15$3.27M0.52569,593 shs21,578 shsCRECre8 Enterprise$3.56+20.9%$2.52$1.68▼$102.18$5.83MN/A498,952 shs469,711 shsISPCiSpecimen$2.81+2.2%$4.39$2.54▼$127.20$4.04M1.62568,963 shs19,822 shsLICNLichen International$2.94+4.2%$4.04$0.75▼$9.49$1.76M-1.24170,783 shs102,120 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNBXApplied Dna Sciences0.00%-15.34%+4.09%-40.90%+45,799,900.00%CRECre8 Enterprise0.00%-5.47%+22.50%-4.55%+293,999,900.00%ISPCiSpecimen0.00%-8.94%-33.73%-65.03%-93.51%LICNLichen International0.00%+55.80%-60.17%-2.42%-34.42%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNBXApplied Dna Sciences$0.45-0.9%$0.51$0.35▼$7.15$3.27M0.52569,593 shs21,578 shsCRECre8 Enterprise$3.56+20.9%$2.52$1.68▼$102.18$5.83MN/A498,952 shs469,711 shsISPCiSpecimen$2.81+2.2%$4.39$2.54▼$127.20$4.04M1.62568,963 shs19,822 shsLICNLichen International$2.94+4.2%$4.04$0.75▼$9.49$1.76M-1.24170,783 shs102,120 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNBXApplied Dna Sciences0.00%-15.34%+4.09%-40.90%+45,799,900.00%CRECre8 Enterprise0.00%-5.47%+22.50%-4.55%+293,999,900.00%ISPCiSpecimen0.00%-8.94%-33.73%-65.03%-93.51%LICNLichen International0.00%+55.80%-60.17%-2.42%-34.42%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNBXApplied Dna Sciences 1.00SellN/AN/ACRECre8 Enterprise 1.00SellN/AN/AISPCiSpecimen 1.00SellN/AN/ALICNLichen International 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest LICN, ISPC, CRE, and BNBX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2026LICNLichen International Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/7/2026LICNLichen International Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)4/24/2026BNBXApplied Dna Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026ISPCiSpecimen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNBXApplied Dna Sciences$2.14M1.53N/AN/A$1.50 per share0.30CRECre8 Enterprise$16.82M0.35$0.44 per share8.07$3.31 per share1.07ISPCiSpecimen$1.03M3.93N/AN/A$14.57 per share0.19LICNLichen International$24.52M0.07N/AN/A$117.75 per share0.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNBXApplied Dna Sciences-$15.16M-$36.76N/AN/AN/A-1,647.25%-349.95%-283.96%N/ACRECre8 Enterprise$680KN/AN/AN/AN/AN/AN/AN/AN/AISPCiSpecimen-$10.49M-$72.26N/AN/AN/A-1,080.16%-584.65%-142.48%8/4/2026 (Estimated)LICNLichen International-$21.96MN/AN/AN/AN/AN/AN/AN/AN/ALatest LICN, ISPC, CRE, and BNBX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q2 2026BNBXApplied Dna SciencesN/A-$0.68N/A-$0.68N/A$1.02 million5/15/2026Q1 2026ISPCiSpecimenN/A-$6.66N/A-$6.66N/A$0.16 million4/28/2026Q4 2025LICNLichen InternationalN/A$14.1750N/A$14.1750N/A$5.13 million4/24/2026Q4 2025CRECre8 EnterpriseN/A-$0.10N/A-$0.10N/A$4.67 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBNBXApplied Dna SciencesN/AN/AN/AN/AN/ACRECre8 EnterpriseN/AN/AN/AN/AN/AISPCiSpecimenN/AN/AN/AN/AN/ALICNLichen InternationalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNBXApplied Dna SciencesN/A1.821.74CRECre8 EnterpriseN/A1.571.57ISPCiSpecimenN/A0.620.62LICNLichen InternationalN/A7.737.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNBXApplied Dna Sciences22.22%CRECre8 EnterpriseN/AISPCiSpecimen13.62%LICNLichen InternationalN/AInsider OwnershipCompanyInsider OwnershipBNBXApplied Dna Sciences6.14%CRECre8 EnterpriseN/AISPCiSpecimen12.20%LICNLichen InternationalN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNBXApplied Dna Sciences707.20 million6.76 millionN/ACRECre8 Enterprise891.64 millionN/AN/AISPCiSpecimen601.44 million1.26 millionNot OptionableLICNLichen International390600,000N/ANot OptionableLICN, ISPC, CRE, and BNBX HeadlinesRecent News About These CompaniesWhat's going on with Lichen China shares on Friday?May 22, 2026 | msn.comLichen International Limited Class AMay 8, 2026 | edition.cnn.comLichen International Limited Announces Financial Results for Fiscal Year 2025April 28, 2026 | markets.businessinsider.comLichen International Limited Class A Ordinary Shares (LICN) Real TimeApril 8, 2026 | nasdaq.comLichen International Ltd.March 24, 2026 | marketwatch.comWhy Lichen International Limited’s (LICN) Stock Is Up 5.92%December 17, 2025 | aaii.comAWhy Lichen International Limited’s (LICN) Stock Is Down 5.85%December 13, 2025 | aaii.comALichen International to hold extraordinary meeting on share capital and governance changesDecember 11, 2025 | msn.comWhy Lichen International Limited’s (LICN) Stock Is Down 9.06%December 10, 2025 | aaii.comALichen International files $500M mixed securities shelfDecember 2, 2025 | msn.comLichen International Limited Adopts 2025 Equity Incentive PlanNovember 7, 2025 | tipranks.comLichen International Secures $18.6 Million Through Private PlacementSeptember 19, 2025 | tipranks.comLichen International Limited Completes Strategic Moves Amid Financial LossesSeptember 19, 2025 | tipranks.comLichen International Settles CEO Debt with Share IssuanceSeptember 10, 2025 | tipranks.comLICN Lichen International LimitedJune 4, 2025 | seekingalpha.comLichen International Ltd. - Ordinary Shares - Class AMarch 4, 2025 | money.usnews.comLichen China Ltd trading halted, news pendingMarch 1, 2025 | markets.businessinsider.comLichen China Limited Announces Effective Date of Reverse Stock Split and Name ChangeFebruary 27, 2025 | prnewswire.comLichen China announces receipt of Nasdaq delisting noticeFebruary 18, 2025 | markets.businessinsider.comLichen China Limited Announces Receipt of Nasdaq Delisting Notice Subject to Hearing RequestFebruary 18, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Up-and-Coming Stocks That Could Be the Next NVIDIABy Chris Markoch | June 1, 2026Microsoft Stock Discount May Be Ending as AI Catalysts BuildBy Chris Markoch | May 25, 2026As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants InBy Leo Miller | May 17, 2026These 3 CLO ETFs Target a Niche Corner of the Fixed-Income MarketBy Nathan Reiff | May 31, 2026From High-Yield to High-Growth: 3 Stocks Boosting DividendsBy Leo Miller | May 18, 2026LICN, ISPC, CRE, and BNBX Company DescriptionsApplied Dna Sciences NASDAQ:BNBX$0.45 0.00 (-0.87%) As of 10:54 AM Eastern This is a fair market value price provided by Massive. Learn more.Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide real-time authentication of molecular tags in the field; and CertainT, which indicates the use of tagging, testing, and tracking platforms and solutions enabling manufacturers, brands, and trade organizations to convey proof of their product claims. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and COVID-19 diagnostic test kit to prevent virus spread within a community, school, or workplace under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. Further, it develops an invasive circulating tumor cell capture and identification technology that uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytes. The company operates in the United States, Europe, Asia, and internationally. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.Cre8 Enterprise NASDAQ:CRE$3.56 +0.62 (+20.92%) As of 10:54 AM Eastern This is a fair market value price provided by Massive. Learn more.Cre8 Enterprise Limited provides integrated financial printing services for listed companies, IPO applicants and private companies in the finance and capital market principally in Hong Kong under its brand, Cre8. The services cover concept creation and artwork design, typesetting, proofreading, translation, printing, binding, logistics arrangement, uploading or making e-submissions of customers' financial reports and compliance documents and media placements. Cre8 Enterprise Limited is based in Hong Kong.iSpecimen NASDAQ:ISPC$2.81 +0.06 (+2.22%) As of 10:50 AM Eastern This is a fair market value price provided by Massive. Learn more.iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.Lichen International NASDAQ:LICN$2.94 +0.12 (+4.18%) As of 10:54 AM Eastern This is a fair market value price provided by Massive. Learn more.Lichen China Limited, together with its subsidiaries, operates as an investment holding company, provides financial and taxation, education support, and software and maintenance services in the People's Republic of China and internationally. The company offers financial and taxation related management consultation, internal control management consultation, annual or regular consultation, and internal training and general consultation services; and education support services, including marketing, operational, and technical support, as well as sells teaching and learning materials. It also provides Lichen Education Accounting Practice System V1.0, a financial and taxation training software, and academic affairs management system to partnered institutions under the partnership agreements, as well as offers software installation, training, and after sales technical and maintenance support services. Lichen China Limited was founded in 2004 and is based in Jinjiang, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Mission Control: Floating In SpaceX's Record-Breaking Orbit 3 Dividend Increases Investors Can Actually Trust SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Meta to Follow Alphabet's Footsteps? What an Equity Raise Could Mean Viasat's Orbiting Profits: Space Force Jackpot? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
